ITM Isotope Technologies Munich SE (ITM), a radiopharmaceutical biotech company, recently announced the signing of a clinical supply agreement for its medical radioisotope no-carrier-added lutetium-177 (n.c.a. 177Lu / EndolucinBeta®) with Y-mAbs Therapeutics, Inc. (Y-mAbs), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. Under the terms of the agreement, ITM will provide its n.c.a. 177Lu for the clinical development of Y-mAbs’ radiopharmaceutical candidate GD2-SADA: 177Lu-DOTA Complex.

To read more please visit:

ITM Signs Clinical Supply Agreement with Y-mAbs for n.c.a. Lutetium-177 (copy 1)

Source: ITM